Information contained in this e-Newsletter should not be considered a substitute for professional diagnosis, treatment or management of S.L.E. and symptoms by a physician.
Missed a previous issue of this e-Newsletter?
You can now view our ARCHIVES.
Editor: Spandan Chakrabarti
|
|
LFNC is an active partner in
|
|
Connect with us on
via "Lupus Online"
|
LFNC's Social Media Program is funded through a generous grant from THE HENRY L. GUENTHER FOUNDATION GEORGE H. SANDY FOUNDATION GLAXOSMITHKLINE |
|
|
|
| You are receiving this newsletter because you have subscribed or have participated in our programs or events. We respect your time and privacy. If you prefer not to continue receiving the newsletter, you can click on the "safe unsubscribe" button below. We hope, however, that you will opt to remain on our newsletter list for important information and life-saving tips that you or someone you know may benefit from now or in the future. |
|
Blisibimod, New Lupus Drug Addressing Severe SLE, Enters Phase 3 Trial
 Blisibimod, a new lupus drug being prepared by Anthera Pharmaceuticals, has entered its Phase 3 clinical studies. In a press release, Anthera Pharmaceuticals describes the study and the promise of the new drug, especially for patients with severe SLE:
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced it has initiated the CHABLIS-SC1 Phase 3 study of blisibimod, a novel inhibitor of B-Cell Activating Factor (BAFF) for the treatment of systemic lupus erythematosus (lupus). Lupus is a chronic autoimmune disease, which often leads to severe skin rash, fatigue, joint pain and major organ complications.
The Phase 3 CHABLIS-SC1 study is a multicenter, placebo-controlled, randomized, double-blind study designed to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in patients with clinically active SLE (SELENA-SLEDAI > 10) who have not achieved optimal resolution of their disease with corticosteroid use. [...]
"The initiation of the CHABLIS-SC1 study marks a critical milestone for Anthera. The insight from our Phase 2b clinical study supports our belief that blisibimod may be a highly effective treatment option for the more severely ill lupus patients compared to currently available therapeutics," said Colin Hislop , MD, Anthera's Chief Medical Officer.
(emphasis ours). Read more about the study here.
|
|
Relaxation and Meditation: There's an app for that!
 We all know how much toll stress can take on patients living with lupus. Yet, stress is a part of everyday life. That's why making it a habit to give yourself time to unwind and relax can be a critical part of living with an autoimmune condition like lupus. And now it turns out that your iPhone can help you relax. Just download the app and get a "sanctuary in your pocket."
Don't have an iPhone? No worries, Oprah Winfrey and Deepak Chopra have also come up with a YouTube video meditation tool that works on all smart phones,tablets and computers. Click image below:
 | | Meditate it Forward - Free Meditation - Pass it On |
|
|
The 5K Teams!
We welcome this year's teams to our 19th Annual 5K Run & Walk. Have you gotten your team in yet?
|
|
Brief Survey: Lupus Support Group for Marin County
A support group is in the works for Marin County, Volunteer facilitators are trying to gauge participant interest and preferences. If you or someone you know might be interested, please complete this brief survey.
|
|
|
|
|
